Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011
Recent diagnostic and cancer reporting changes influencing myeloproliferative neoplasms (MPNs) encourage the assessment of trends and examination of the recently identified MPN subtypes: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), across the age continuum by race and ethnicity.
Surveillance, Epidemiology, and End Results data provided MPN incidence data since 1973 and MPN subtype data since 2001. Joinpoint regression estimated annual percent changes. Poisson regression estimated risk ratios.
The 2005 JAK2 V617F discovery and the 2008 WHO diagnostic guideline for the JAK2 V617F mutation coincide with a 31 % increase in ET and a 21 % decrease in PV incidence rates. We found that younger women had a 13–33 % higher ET risk and that women under the age of 34 had a 58 % higher PMF risk, relative to men. Blacks, aged 35–49 with a higher ET risk, also had a 69 % higher PMF risk relative to whites.
Demographic characteristic of ET and PMF patients may be useful for improving risk prediction and informing clinical screening and treatment strategies. Changing guidelines, new discoveries, and in-depth analysis of a large population-based study have implications for accurately identifying incident cases of MPNs, MPN subgroups, and health resource planning.
KeywordsMyeloproliferative neoplasm Polycythemia vera Essential thrombocythemia Primary myelofibrosis Incidence Trends
Conflict of interest
The authors claim no conflict of interest.
This research was declared exempt from the Office of Research Integrity at the University of Nevada, Reno.
- Alvarez-Larrán BB, Pereira A, Kerguelen A, Hernández-Boluda JC, Martínez-Avilés L et al (2014) JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol 89:517–523CrossRefPubMedGoogle Scholar
- Craig BM, Rollison DE, List AF, Cogle CR (2012) Underreporting of myeloid malignancies by united states cancer registries. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 21:474–481Google Scholar
- Joinpoint Regression Program, Version 18.104.22.168—February (2015) Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer InstituteGoogle Scholar
- NAACCR Race and Ethnicity Work Group (2014) NAACCR Guideline for enhancing hispanic/latino identification: revised NAACCR hispanic/latino identification algorithm[NHIA v2.2.1].Springfield (IL): North American Association of Central Cancer RegistriesGoogle Scholar
- National Cancer Institute (2013) SEER (Surveillance, Epidemiology and End Results). http://seer.cancer.gov/registries/data.html. Accessed 15 December 2014
- NCI. Cancer Trends Progress Report-2011/2012 Update (2012) National Cancer Institute, NIH, DHHS, Bethesda, MD http://progressreport.cancer.gov. Accessed 14 December 2014
- SAS/STAT software, Version 9.3 of the SAS System for PC. (2014) SAS Institute Inc., Cary, NC, USAGoogle Scholar
- SEER (2015) Fast stats: an interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. http://seer.cancer.gov/faststats. Accessed 10 March 2015
- Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: incidence—SEER 9 Regs Research Data, Nov 2013 Sub (1973–2011) <Katrina/Rita Population Adjustment>- Linked To County Attributes—Total US, 1969-2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014, based on the November 2013 submission. www.seer.cancer.gov. Accessed 16 Sept 2014